| 项目编号 |
PRJCA013651 |
| 项目标题 |
mRNA expression profiles of BT474 cells after the treatment of pyrotinib, tamoxifen, dalpiciclib and their combination |
| 涉及领域 |
Medical |
| 数据类型 |
Transcriptome or Gene expression
|
| 物种名称 |
Homo sapiens
|
| 描述信息 |
The HER2+HR+ BT474 cells were treated with DMSO(control group), pyrotinib, tamoxifen, dalpiciclib, pyrotinib+tamoxifen, pyrotinib+dalpiciclib, tamoxifen+dalpiciclib and pyrotinib+tamoxifen+dalpiciclib. The mRNA expression of BT474 cells treated with different drugs mentioned above were sequenced and uploaded. In the expression matrix we uploaded, A stands for pyrotinib treatment, B stands for tamoxifen treatment, C stands for dalpiciclib treatment, AB stands for pyrotinib+tamoxifen treatment, AC stands for pyrotinib+dalpiciclib treatment, BC stands for tamoxifen+dalpiciclib treatment and ABC stands for pyrotinib+tamoxifen+dalpiciclib treatment. |
| 样品范围 |
Monoisolate |
| 发布日期 |
2023-03-13 |
| 出版信息 |
| PubMed ID |
文章标题 |
杂志名称 |
Doi |
发表年份 |
| 36602226
|
Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2+HR+ breast cancer
|
eLife
|
10.7554/eLife.85246
|
2023
|
|
|
| 项目资金来源 |
| 机构 |
项目类型 |
授权项目ID |
授权项目名称 |
| National Natural Science Foundation of China (NSFC)
|
General Program
|
U20A20381
|
|
|
|
| 提交者 |
Caigang
Liu (liucg@sj-hospital.org)
|
| 提交单位 |
Shengjing Hospital of China Medical University |
| 提交日期 |
2022-12-04 |
